Pancreatic Cancer Data in One Page… Unknown Bio Stock Soars 50% in a Day

Tango Therapeutics, Inc. (NASDAQ: TNGX), a U.S.–listed clinical-stage biotech, saw its share price surge past $30.51 intraday on June 8—an increase of more than 50% from the previous day—on unusually heavy trading of roughly 14 million shares. That jump lifted the company’s market capitalization to about $4.4 billion (approximately ₩6 trillion).

The rally followed the release of early clinical data showing that the combination of vopimetostat and Revolution Medicines’ RAS(ON) inhibitor achieved a 92% objective response rate and a six-month progression-free survival rate of 90% in patients with MTAP-deficient, RAS-mutated metastatic pancreatic cancer. These results highlight the regimen’s potential to replace standard chemotherapy. After the market closed that same day, Tango Therapeutics also announced a proposed $500 million common stock offering (around ₩700 billion), underscoring both its plans to strengthen its balance sheet and the prospect of shareholder dilution.

Based in Boston, Tango Therapeutics is a precision oncology company that exploits synthetic lethality to target genetic vulnerabilities in cancer cells. Its early-stage pipeline includes the PRMT5 inhibitor vopimetostat, aimed at MTAP-deficient pancreatic and lung cancers, and TNG456, a candidate for treating brain tumors.